Patient
SITE004-0041
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE004 (DEU) (Dr. Tanaka)
consented 2025-10-11
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 4
Grade 1 Alopecia — outcome: UNKNOWN; onset 2023-01-18 (study day 267); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 235); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: NOT RELATED
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: RELATED
Data queries 1
2 adverse event records for SITE004-0041 share preferred term Anaemia and onset 2025-12-04. Duplicate entry; the first record (entered 2025-12-04) is kept.
Auto-closed by AE-007 (duplicate AE record): first of 2 identical records kept; the 1 later copy flagged for the site to delete or differentiate.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.